Revenue collapsed to $898.0K in 2026Q2 from $94.7M in 2024Q2 while R&D and SG&A of $45.9M produced a -50.1% operating margin, and gross margin swung violently from 100.0% to -22.8% across the period, indicating no stable cost-to-revenue foundation.
Entrada Therapeutics, Inc. (TRDA) annual income statement — 7-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Sales/Revenue | 3.98M | 25.42M | 210.78M | 129.01M | 0 | 0 | 0 | 0 |
| Revenue Growth % | -93.54% | -87.94% | 63.38% | - | - | - | - | - |
| Cost of Goods Sold | 1.69M | 4.1M | 0 | 0 | 0 | 0 | 326K | 104K |
| COGS % of Revenue | - | 16.11% | - | - | - | - | - | - |
| Gross Profit | 2.29M | 21.32M | 210.78M | 129.01M | 0 | 0 | -326K | -104K |
| Gross Margin % | 57.48% | 83.89% | 100% | 100% | - | - | - | - |
| Gross Profit Growth % | - | -89.88% | 63.38% | - | - | 100% | -213.46% | - |
| Operating Expenses | 173.45M | 177.32M | 163.77M | 132.18M | 97.25M | 51.13M | 26.34M | 11.82M |
| OpEx % of Revenue | - | 697.55% | 77.7% | 102.45% | - | - | - | - |
| Selling, General & Admin | 40.39M | 41.05M | 38.47M | 32.29M | 30.64M | 15.2M | 5.24M | 3.61M |
| SG&A % of Revenue | - | 161.48% | 18.25% | 25.03% | - | - | - | - |
| Research & Development | 134.75M | 142.27M | 125.31M | 99.88M | 66.61M | 35.93M | 21.1M | 8.22M |
| R&D % of Revenue | - | 559.65% | 59.45% | 77.42% | - | - | - | - |
| Other Operating Expenses | -1.69M | -6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -171.16M | -156M | 47.01M | -3.16M | -97.25M | -51.13M | -26.67M | -11.82M |
| Operating Margin % | -4303.82% | -613.66% | 22.3% | -2.45% | - | - | - | - |
| Operating Income Growth % | - | -431.83% | 1586.75% | 96.75% | -90.21% | -91.72% | -125.53% | - |
| EBITDA | -170.33M | -151.9M | 50.78M | -321K | -95.35M | -50.01M | -26.34M | -11.72M |
| EBITDA Margin % | -4282.83% | -597.55% | 24.09% | -0.25% | - | - | - | - |
| EBITDA Growth % | -45.14% | -399.11% | 15920.56% | 99.66% | -90.67% | -89.86% | -124.75% | - |
| D&A (Non-Cash Add-back) | -1.14M | 4.1M | 3.77M | 2.84M | 1.9M | 1.12M | 326K | 104K |
| EBIT | -161.19M | -142.83M | 66.48M | 12.06M | -91.98M | -51.16M | -26.52M | -11.82M |
| Net Interest Income | 9.97M | 0 | 19.47M | 15.22M | 0 | 0 | 0 | 0 |
| Interest Income | 9.97M | 0 | 19.47M | 15.22M | 2.63M | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 2.63M | 0 | 0 | 0 |
| Other Income/Expense | 9.97M | 13.17M | 19.47M | 15.22M | 2.63M | -31K | 144K | 6.72M |
| Pretax Income | -161.19M | -142.83M | 66.48M | 12.06M | -94.62M | -51.16M | -26.52M | -5.1M |
| Pretax Margin % | -4053.16% | -561.84% | 31.54% | 9.34% | - | - | - | - |
| Income Tax | 192K | 924K | 859K | 18.74M | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.12% | -0.65% | 1.29% | 155.45% | 0% | 0% | 0% | 0% |
| Net Income | -161.39M | -143.75M | 65.63M | -6.68M | -94.62M | -51.16M | -26.52M | -4.65M |
| Net Margin % | -4057.98% | -565.48% | 31.13% | -5.18% | - | - | - | - |
| Net Income Growth % | -56% | -319.04% | 1081.69% | 92.93% | -84.95% | -92.88% | -470.51% | - |
| Net Income (Continuing) | -161.39M | -143.75M | 65.63M | -6.68M | -94.62M | -51.16M | -26.52M | -5.1M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.81 | -3.47 | 1.68 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| EPS Growth % | -54.39% | -306.55% | 940% | 92.83% | -74.38% | -90.48% | 81.08% | - |
| EPS (Basic) | - | -3.47 | 1.76 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| Diluted Shares Outstanding | 42.37M | 41.37M | 39M | 33.05M | 31.29M | 31.22M | 31.25M | 1.05M |
| Basic Shares Outstanding | 42.37M | 41.37M | 37.31M | 33.05M | 31.29M | 31.22M | 31.25M | 1.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying TRDA stock.
For fiscal year 2025, Entrada Therapeutics, Inc. (TRDA) reported total revenue of $25.4M.
Entrada Therapeutics, Inc. (TRDA) reported a net loss of $143.8M for the fiscal year ending 2025.
Entrada Therapeutics, Inc. (TRDA) reported an operating income of $-156.0M, resulting in an operating profit margin of -613.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Entrada Therapeutics, Inc. (TRDA) generated $21.3M in gross profit for the year, representing a gross profit margin of 83.9%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Losses outpacing revenue recovery
Metrics are mathematically derived from official filings.
Top Line Collapsed to Immateriality
Entrada's quarterly revenue collapsed from $94.7M in 2024Q2 to $898.0K in 2026Q2, with the most recent quarter declining 53.9% year over year, according to reported income statements, suggesting whatever previously drove the top line has largely evaporated.
The sequence of growth rates (-10.6%, -55.3%, -65.2%, -97.9%, -91.8%, -96.5%, -95.7%, -53.9%) points to a one-time revenue source that exhausted itself during 2024 rather than a business scaling with adoption, since the deceleration was abrupt and has not meaningfully reversed. Importantly, the most recent 'improvement' to -53.9% growth comes off an already tiny base of $875K, so investors should treat it as a low-base artifact rather than evidence of a genuine recovery trajectory.
Gross Margin Lacks Stable Foundation
As reported in TRDA's financial statements, gross margin swung from 100.0% in 2025Q2 to -22.8% in 2025Q3 when $38.4M of COGS met $1.6M of revenue, then to 8.0% in 2026Q1, signaling no stable cost-to-revenue relationship.
The recurring 100.0% gross margin quarters reflect periods with zero recorded COGS, which suggests revenue is likely non-product in nature (for example, licensing or milestone recognition) rather than manufactured product sales. The $38.4M COGS charge in 2025Q3, roughly 24x that quarter's revenue, may indicate a write-off or cost absorption tied to a specific event; because it is not yet clear whether such charges recur, any normalized margin assumption warrants further investigation.
R&D Absorbs an Unsustainable Share
Based on Entrada's reported figures, R&D expense climbed from $28.6M in 2024Q1 to $35.4M in 2026Q2 while SG&A held near $10M, leaving the company absorbing roughly $46M of quarterly operating costs against sub-$1M revenue, a ratio that dominates the P&L.
SG&A discipline appears genuine, moving only from $9.4M to $10.5M across ten quarters, which implies management has kept overhead contained while directing spending toward pipeline work. R&D, however, grew about 24% even as revenue fell more than 98%, meaning the expense base appears deliberately decoupled from current commercial output — a posture that only makes sense if management believes pipeline value can eventually replace the lost revenue, though the income statement alone cannot confirm that.
Non-Operating Items Flatter Net Loss
Stock-based compensation reached $9.9M in 2026Q2 versus $3.7M in 2024Q1, while the $42.8M net loss trailed the $45.0M operating loss, suggesting non-operating items are cushioning reported earnings, based on Entrada's disclosed income statements, warranting closer inspection.
The consistent gap between operating and net results — for instance, 2025Q1's -$21.8M operating loss reported as -$17.3M net loss, and 2024Q2's $53.4M operating income reported as $55.0M net income — implies a recurring non-operating contribution, plausibly interest income, that is propping up the bottom line independent of operations. With SBC more than doubling to $9.9M in 2026Q2 and representing a substantial share of the $45.0M operating loss, dilution-adjusted economics look weaker than headline EPS of -$1.01 conveys.
Peak-Earnings Era May Be Behind
The strongest challenge to TRDA's narrative is that 2024's profitability — $55.0M net income on $94.7M revenue in 2024Q2 — appears episodic, since subsequent quarters show operating losses near $42M with revenue under $2M, based on reported figures.
A short-seller would likely emphasize that the operating loss has proven sticky at $42M–$47M per quarter across eight consecutive periods while revenue fell to negligible levels, so cost structure has not adjusted in proportion to the revenue loss and losses appear structurally entrenched rather than transitional. They would also note that gross margin of 100.0% in five of ten quarters, when revenue is this small, offers no evidence of pricing power or durable unit economics, and may indicate that peer comparisons on margin (peers such as ARWR and EDIT also post 100% gross margins) mask very different underlying revenue quality.